Loading...
XLON
DXRX
Market cap154mUSD
Dec 05, Last price  
137.00GBP
1D
1.11%
1Q
-4.20%
IPO
40.51%
Name

Diaceutics PLC

Chart & Performance

D1W1MN
XLON:DXRX chart
P/E
P/S
3.60
EPS
Div Yield, %
Shrs. gr., 5y
5.65%
Rev. gr., 5y
19.06%
Revenues
32m
+35.69%
1,397,5744,588,6987,370,60810,373,18013,442,12112,696,00013,943,00019,504,00023,699,00032,158,000
Net income
-2m
L-2.46%
-103,488747,139663,193632,307398,000263,000561,000724,000-1,746,000-1,703,000
CFO
651k
-50.34%
0674,0141,534,168-954,038-627,054253,000570,0005,148,0001,311,000651,000

Notes

No notes on this company yet
Write a private note on this company, for your eyes only

Profile

Diaceutics PLC, a diagnostic commercialization company, provides data, data analytics, and implementation services for pharmaceutical companies worldwide. It operates DXRX platform, which offers DXRX data solutions, including access to various pipelines of diagnostic testing data from a network of laboratories that provides DXRX signal, lab mapping, testing dashboard, and physician mapping services; DXRX marketplace solutions, which enables a marketplace, where labs, pharma, and diagnostic companies come to find partners for collaborations on precision medicine diagnostics. The company also provides DXRX patient journey that enables pharma customers to complete a longitudinal analysis of biomarker testing journeys of individual patients, which identifies opportunities for earlier testing and treatment; DXRX lab benchmarking that enables laboratories to gain competitive edge and compare key criteria to others in the industry providing metrics, such as disease, testing and methodology, market share, turnaround time, and laboratory leadership in these areas; DXRX test reimbursement, which enables pharma customers to engage with laboratories to fund the introduction of novel companion diagnostics, as well as reducing the lag time in test adoption; and DXRX test signal that delivers a real-time alert of a testing event, which allows pharma customers to identify therapeutically actionable patients in the previous weeks. In addition, it offers diagnostic landscape, planning, implementation, and tracking services; and consulting services for precision medicine diagnostics. Further, the company provides test standardization, test quality assessment, test report optimization, laboratory tech support, test access and reimbursement, laboratory training, and educational resources services. Diaceutics PLC was incorporated in 2005 and is headquartered in Belfast, the United Kingdom.
IPO date
Mar 21, 2019
Employees
151
Domiciled in
GB
Incorporated in
GB

Valuation

Title
GBP in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2024‑122023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑122015‑12
Income
Revenues
Cost of revenue
Unusual Expense (Income)
NOPBT
NOPBT Margin
Operating Taxes
Tax Rate
NOPAT
Net income
Dividends
Dividend yield
Proceeds from repurchase of equity
BB yield
Debt
Debt current
Long-term debt
Deferred revenue
Other long-term liabilities
Net debt
Cash flow
Cash from operating activities
CAPEX
Cash from investing activities
Cash from financing activities
FCF
Balance
Cash
Long term investments
Excess cash
Stockholders' equity
Invested Capital
ROIC
ROCE
EV
Common stock shares outstanding
Price
Market cap
EV
EBITDA
EV/EBITDA
Interest
Interest/NOPBT